THBS1 and familial pancreatic carcinoma: AACT could be used as a biomarker for the diagnosis of pancreatic cancer, and the combination of AACT, thrombospondin-1 (THBS1) and peptides containing single amino acid variants (SAAVs) has shown an improved diagnostic performance in the identification of pancreatic cancer from healthy controls, with an AUC of 0.98, which was demonstrated to improve the survival rate if diagnosed at an early stage [15].